DRAPALIN

What DRAPALIN does

DRAPALIN Pharmaceuticals GmbH is a Munich-based importer and pharmaceutical wholesaler of medical cannabis, founded in December 2017 by a five-person team (Ilya Harev, Lana Korneva, Anna-Sophie Kavar, Konstantin Lubsky, Ivan Harev) in direct response to Germany's March 2017 'Cannabis as Medicine' law. The company distributes EU-GMP-certified cannabis flowers and CBD/THC extracts to over 300 partner pharmacies across Germany under a full regulatory stack issued by the Government of Upper Bavaria: a §52a AMG wholesale permit, GDP certificate, §67(1) i.V.m. §64(3g) AMG active substance manufacturer registration, §3 BtMG narcotics license, and §4 MedCanG permit. Ordering is executed through a DocCheck-authenticated Medical Community portal plus phone, fax, and email channels, with new pharmacy customers required to upload business licenses and allocation letters.

The company's underlying technology is rooted in pharmaceutical process control rather than software: documented capabilities include supercritical CO2 extraction, ethanol-based extraction across cryogenic, room-temperature, cold, hot, and ultrasound-assisted variants, and independent laboratory quality control via HPLC and GC analysis for cannabinoid content, terpene profiling, solvent residues, and microbiological safety. Product input is sourced from international EU-GMP-certified producers including Beyond-Buds (South Africa), Castle Rock Farm (Canada), sinceritas (Slovenia), and Uncle Rooneys. Drapalin also operates a side business in GMP certification consulting for cannabis producers and sells specialized professional literature through a separate online shop, but the wholesale-to-pharmacy transaction remains the core revenue mechanism. The company is privately held, founder-controlled, with no disclosed institutional funding or external shareholders.

Name

DRAPALIN

Legal name

Drapalin Pharmaceuticals GmbH

Website

https://drapalin.de

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

DRAPALIN Pharmaceuticals GmbH is a Munich-based pharmaceutical wholesaler that imports and distributes EU-GMP-certified medical cannabis flowers and extracts to over 300 pharmacies across Germany under a full stack of AMG, GDP, BtMG, and MedCanG permits.

Ownership category

akta.pro rank

Product category

Pharmaceutical Wholesale Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Medical cannabis wholesale
• Pharmaceutical distribution
• Cannabis flower supply
• EU-GMP certified products
• Cannabis extracts

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Medical cannabis wholesale: Wholesale distribution of medical cannabis flowers and extracts to pharmacies throughout Germany. Products produced according to EU-GMP quality standards.
2. Specialty literature and products: Sale of specialized medical literature and related products through the Drapalin online shop (drapalin-shop.de).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

DRAPALIN Pharmaceuticals GmbH imports and wholesales medical cannabis flowers and extracts produced under EU-GMP standards to pharmacies across Germany. The company operates a GDP-compliant distribution network serving over 300 partner pharmacies and provides informational support for medical professionals. Additional offerings include specialized medical literature through an online shop and GMP certification consulting for cannabis producers.

Product overview

DRAPALIN operates as a medical cannabis wholesaler offering a portfolio centered on pharmaceutical-grade cannabis flowers and related products. The core offering consists of medical cannabis flowers (Medizinisches Cannabis) sourced from EU-GMP certified producers, with plans to expand into prescription CBD/THC extracts. Supporting the core products, DRAPALIN provides specialized professional literature through its online shop and offers GMP certification consulting services to other cannabis producers. The company distributes exclusively to pharmacies through a secured medical community portal, not directly to patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Cannabis Flowers Dried cannabis flowers (Cannabis sativa L.) produced under EU-GMP quality standards, available in various strains with differing THC and CBD compositions for therapeutic use by patients with valid BtM prescriptions.
• CBD/THC Extracts Prescription-only CBD and THC extracts produced using advanced extraction methods (supercritical CO2 and cryogenic ethanol) yielding full-spectrum cannabinoid formulations with preserved terpenes.
• GMP Certification Consulting Consulting services for cannabis producers seeking GMP (Good Manufacturing Practice) certification, including audit preparation and corrective action support, leveraging DRAPALIN's regulatory expertise.
• Specialized Medical Literature Selected professional literature on medical cannabis sold through the Drapalin online shop (drapalin-shop.de), serving as an information resource for healthcare professionals.

Quantifiable outcome

• Over 300 partner pharmacies served in Germany

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor.

• TSV 1860 MünchenminorOthersSports club partnership displayed on company website. Nature of partnership not detailed in available content.
• Coliquio GmbHminorGTM or Marketing PartnerProfessional medical community platform partnership displayed as logo on website. Coliquio is a medical professional network.
• Beyond-BudsminorStrategic or Co-development PartnerInternational cannabis company partnership displayed as logo. Nature of collaboration not detailed.
• sinceritasminorStrategic or Co-development PartnerEuropean pharmaceutical/cannabis company partnership displayed as logo on website.
• Castle Rock FarmminorStrategic or Co-development PartnerInternational cannabis producer partnership displayed as logo. Company appears to be BC Green based on URL link.
• Uncle RooneysminorChannel Partner/ Reseller/ DistributorInternational cannabis company partnership displayed as logo. Nature of distribution relationship not detailed.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Tilray Brands (Germany operations): Global cannabis major with established German medical cannabis distribution operations. Competes with DRAPALIN as a broad incumbent offering scale, capital, and a wider product portfolio to German pharmacies.
• Aurora Cannabis Europe: European arm of Canadian cannabis producer Aurora, active in German medical cannabis distribution. Broad incumbent competing with DRAPALIN via imported EU-GMP flowers into the same pharmacy channel.
• Sanity Group GmbH: Berlin-based cannabis holding company operating across medical and consumer cannabis segments in Germany. Competes with DRAPALIN in medical cannabis distribution as part of a broader portfolio.

Direct peers

• Cantourage GmbH: Berlin-based medical cannabis importer and distributor serving German pharmacies with EU-GMP flowers and extracts. Direct competitor to DRAPALIN with the same B2B pharmacy wholesale model and similar reliance on international supplier partnerships.
• Four20 Pharma GmbH: German medical cannabis producer and wholesaler with its own GMP-certified cultivation. Competes with DRAPALIN at the pharmacy wholesale level, with a vertically integrated supply chain.
• Demecan Holding GmbH: Vertically integrated German medical cannabis producer and distributor with domestic cultivation. Overlaps with DRAPALIN in wholesale to German pharmacies but also competes upstream in supply.
• Nimbus Health GmbH (Grünhorn): German medical cannabis pharmacy and distribution platform supplying pharmacies and patients. Direct competitor in the medical cannabis wholesale and pharmacy services space serving Germany.
• Cansativa GmbH: German medical cannabis distribution platform and wholesaler supplying pharmacies nationwide. Competes directly with DRAPALIN on B2B wholesale of medical cannabis flowers to German Apotheken.
• Cannamedical Pharma GmbH: Cologne-based medical cannabis wholesaler and importer serving German pharmacies with EU-GMP certified flowers. Directly comparable B2B wholesale model and customer base.

Emerging players

• Bloomwell Group GmbH: Frankfurt-based German medical cannabis platform combining pharmacy network, telemedicine, and wholesale distribution. Emerging player with overlapping B2B pharmacy customer base and similar focus on the German medical cannabis market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/drapalin
• Facebookfacebook.com/DRAPALINPharma
• LinkedInlinkedin.com/company/drapalin

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DRAPALIN